Home
About
Overview
Sharing Data
ORCID
Help
History (1)
First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors.
First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. 2018 01 15; 124(2):315-324.
View in:
PubMed
subject areas
Adult
Aged
Bayes Theorem
Female
Humans
Indoles
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
Pyrimidinones